Complementary and synergistic activities of anti-V3, CD4bs and CD4i antibodies derived from a single individual can cover a wide range of HIV-1 strains

Virology

Volumn 475, Issue , 2015, Pages 187-203

  Ramirez Valdez, Kristel Paola ^a   Kuwata, Takeo ^a   Maruta, Yasuhiro ^a   Tanaka, Kazuki ^a   Alam, Muntasir ^a   Yoshimura, Kazuhisa ^a,b   Matsushita, Shuzo ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

Author keywords

ADCC activity; Conventional antibodies; HIV 1; Neutralizing antibodies; Synergy

Indexed keywords

CD4B ANTIBODY; CD4I ANTIBODY; EPITOPE; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; V3 ANTIBODY; CD4 ANTIGEN; GLYCOPROTEIN GP 120; GP120 PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; HIV ENVELOPE PROTEIN GP120 (305-321); HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; NEUTRALIZING ANTIBODY; PEPTIDE FRAGMENT;

ANTIBODY ISOLATION; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ARTICLE; BINDING COMPETITION; BINDING SITE; CELL MEDIATED CYTOTOXICITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMORAL IMMUNITY; IMMUNOGLOBULIN VARIABLE REGION; NONHUMAN; PROTEIN FUNCTION; SOMATIC MUTATION; VIRUS NEUTRALIZATION; ANTIBODY AFFINITY; ANTIBODY COMBINING SITE; CLASSIFICATION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; PHYSIOLOGY; VIROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; ANTIGENS, CD4; BINDING SITES, ANTIBODY; EPITOPES; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; PEPTIDE FRAGMENTS;

EID: 84918791942     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2014.11.011     Document Type: Article

References (121)

1. Alpert M.D., Heyer L.N., Williams D.E.J., Harvey J.D., Greenough T., Allhorn M., Evans D.T. A novel assay for antibody-dependent cell-mediated cytotoxicity against HIV-1- or SIV-infected cells reveals incomplete overlap with antibodies measured by neutralization and binding assays. J. Virol. 2012, 86:12039-12052. 10.1128/JVI.01650-12.
2. Andrabi R., Williams C., Wang X.-H., Li L., Choudhary A.K., Wig N., Biswas A., Luthra K., Nadas A., Seaman M.S., Nyambi P., Zolla-Pazner S., Gorny M.K. Cross-neutralizing activity of human anti-V3 monoclonal antibodies derived from non-B clade HIV-1 infected individuals. Virology 2013, 439:81-88. 10.1016/j.virol.2012.12.010.
3. Banerjee K., Klasse P.J., Sanders R.W., Pereyra F., Michael E., Lu M., Walker B.D., Moore J.P. IgG subclass profiles in infected HIV type 1 controllers and chronic progressors and in uninfected recipients of Env vaccines. AIDS Res. Hum. Retroviruses 2010, 26:445-458. 10.1089/aid.2009.0223.
4. Bar K.J., Tsao C., Iyer S.S., Decker J.M., Yang Y., Bonsignori M., Chen X., Hwang K.-K., Montefiori D.C., Liao H.-X., Hraber P., Fischer W., Li H., Wang S., Sterrett S., Keele B.F., Ganusov V.V., Perelson A.S., Korber B.T., Georgiev I., McLellan J.S., Pavlicek J.W., Gao F., Haynes B.F., Hahn B.H., Kwong P.D., Shaw G.M. Early low-titer neutralizing antibodies impede HIV-1 replication and select for virus escape. PLoS Pathog. 2012, 8:e1002721. 10.1371/journal.ppat.1002721.
5. Barbas C.F., Burton D.R., Scott J.K., Silverman G.J. Phage Display: A Laboratory Manual 2001, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York.
6. Barouch D.H., Whitney J.B., Moldt B., Klein F., Oliveira T.Y., Liu J., Stephenson K.E., Chang H.-W., Shekhar K., Gupta S., Nkolola J.P., Seaman M.S., Smith K.M., Borducchi E.N., Cabral C., Smith J.Y., Blackmore S., Sanisetty S., Perry J.R., Beck M., Lewis M.G., Rinaldi W., Chakraborty A.K., Poignard P., Nussenzweig M.C., Burton D.R. Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature 2013, 503:224-228.
7. Binley J.M., Lybarger E.A., Crooks E.T., Seaman M.S., Gray E., Davis K.L., Decker J.M., Wycuff D., Harris L., Hawkins N., Wood B., Nathe C., Richman D., Tomaras G.D., Bibollet-Ruche F., Robinson J.E., Morris L., Shaw G.M., Montefiori D.C., Mascola J.R. Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J. Virol. 2008, 82:11651-11668. 10.1128/JVI.01762-08.
8. Bonsignori M., Hwang K.-K., Chen X., Tsao C.-Y., Morris L., Gray E., Marshall D.J., Crump J.A., Kapiga S.H., Sam N.E., Sinangil F., Pancera M., Yongping Y., Zhang B., Zhu J., Kwong P.D., O'Dell S., Mascola J.R., Wu L., Nabel G.J., Phogat S., Seaman M.S., Whitesides J.F., Moody M.A., Kelsoe G., Yang X., Sodroski J., Shaw G.M., Montefiori D.C., Kepler T.B., Tomaras G.D., Alam S.M., Liao H.-X., Haynes B.F. Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. J. Virol. 2011, 85:9998-10009. 10.1128/JVI.05045-11.
9. Boyer S. Financial barriers to HIV treatment in Yaounde, Cameroon: first results of a national cross-sectional survey. Bull. World Health Organ. 2009, 87:279-287. 10.2471/BLT.07.049643.
10. Burton D.R., Barbas C.F., Persson M.a., Koenig S., Chanock R.M., Lerner R.a. A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals. Proc. Natl. Acad. Sci. U.S.A. 1991, 88:10134-10137.
11. Buzon M.J., Massanella M., Llibre J.M., Esteve A., Dahl V., Puertas M.C., Gatell J.M., Domingo P., Paredes R., Sharkey M., Palmer S., Stevenson M., Clotet B., Blanco J., Martinez-Picado J. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat. Med. 2010, 16:460-465.
12. Choe H., Li W., Wright P.L., Vasilieva N., Venturi M., Huang C.-C., Grundner C., Dorfman T., Zwick M.B., Wang L., Rosenberg E.S., Kwong P.D., Burton D.R., Robinson J.E., Sodroski J.G., Farzan M. Tyrosine sulfation of human antibodies contributes to recognition of the CCR5 binding region of HIV-1 gp120. Cell 2003, 114:161-170.
13. Chou T.C., Talaly P. A simple generalized equation for the analysis of multiple inhibitions of Michaelis-Menten kinetic systems. J. Biol. Chem. 1977, 252:6438-6442.
14. Corti D., Langedijk J.P.M., Hinz A., Seaman M.S., Vanzetta F., Fernandez-Rodriguez B.M., Silacci C., Pinna D., Jarrossay D., Balla-Jhagjhoorsingh S., Willems B., Zekveld M.J., Dreja H., O'Sullivan E., Pade C., Orkin C., Jeffs S.a., Montefiori D.C., Davis D., Weissenhorn W., McKnight A., Heeney J.L., Sallusto F., Sattentau Q.J., Weiss R.a., Lanzavecchia A. Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS One 2010, 5:e8805. 10.1371/journal.pone.0008805.
15. Decker J.M., Bibollet-Ruche F., Wei X., Wang S., Levy D.N., Wang W., Delaporte E., Peeters M., Derdeyn C.A., Allen S., Hunter E., Saag M.S., Hoxie J.A., Hahn B.H., Kwong P.D., Robinson J.E., Shaw G.M. Antigenic conservation and immunogenicity of the HIV coreceptor binding site. J. Exp. Med. 2005, 201:1407-1419. 10.1084/jem.20042510.
16. Deeks S.G., Schweighardt B., Wrin T., Galovich J., Hoh R., Sinclair E., Hunt P., McCune J.M., Martin J.N., Petropoulos C.J., Hecht F.M. Neutralizing antibody responses against autologous and heterologous viruses in acute versus chronic human immunodeficiency virus (HIV) infection: evidence for a constraint on the ability of HIV to completely evade neutralizing antibody responses. J. Virol. 2006, 80:6155-6164. 10.1128/JVI.00093-06.
17. Derdeyn C.A., Decker J.M., Sfakianos J.N., Wu X., Brien W.A.O., Ratner L., John C., Shaw G.M., Hunter E., O'Brien W.A., Kappes J.C. Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J. Virol. 2000, 74:8358-8367. 10.1128/JVI.74.18.8358-8367.2000.
18. DeVico A., Fouts T., Lewis G.K., Gallo R.C., Godfrey K., Charurat M., Harris I., Galmin L., Pal R. Antibodies to CD4-induced sites in HIV gp120 correlate with the control of SHIV challenge in macaques vaccinated with subunit immunogens. Proc. Natl. Acad. Sci. U.S.A 2007, 104:17477-17482. 10.1073/pnas.0707399104.
19. Dhillon A.K., Donners H., Pantophlet R., Johnson W.E., Decker J.M., Shaw G.M., Lee F.-H., Richman D.D., Doms R.W., Vanham G., Burton D.R. Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors. J. Virol. 2007, 81:6548-6562. 10.1128/JVI.02749-06.
20. Doria-Rose N.A., Klein R.M., Daniels M.G., O'Dell S., Nason M., Lapedes A., Bhattacharya T., Migueles S.a., Wyatt R.T., Korber B.T., Mascola J.R., Connors M. Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables. J. Virol. 2010, 84:1631-1636. 10.1128/JVI.01482-09.
21. Doria-Rose N.A., Klein R.M., Manion M.M., O'Dell S., Phogat A., Chakrabarti B., Hallahan C.W., Migueles S.a., Wrammert J., Ahmed R., Nason M., Wyatt R.T., Mascola J.R., Connors M. Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies. J. Virol. 2009, 83:188-199. 10.1128/JVI.01583-08.
22. Eda Y., Murakami T., Ami Y., Nakasone T., Takizawa M., Someya K., Kaizu M., Izumi Y., Yoshino N., Matsushita S., Higuchi H., Matsui H., Shinohara K., Takeuchi H., Koyanagi Y., Yamamoto N., Honda M. Anti-V3 humanized antibody KD-247 effectively suppresses ex vivo generation of human immunodeficiency virus type 1 and affords sterile protection of monkeys against a heterologous simian/human immunodeficiency virus infection. J. Virol. 2006, 80:5563-5570. 10.1128/JVI.02095-05.
23. Eda Y., Takizawa M., Murakami T., Maeda H., Kimachi K., Yonemura H., Koyanagi S., Shiosaki K., Higuchi H., Makizumi K., Nakashima T., Osatomi K., Tokiyoshi S., Matsushita S., Yamamoto N., Honda M. Sequential immunization with V3 peptides from primary human immunodeficiency virus type 1 produces cross-neutralizing antibodies against primary isolates with a matching narrow-neutralization sequence motif. J. Virol. 2006, 80:5552-5562. 10.1128/JVI.02094-05.
24. Gnanakaran S., Daniels M.G., Bhattacharya T., Lapedes A.S., Sethi A., Li M., Tang H., Greene K., Gao H., Haynes B.F., Cohen M.S., Shaw G.M., Seaman M.S., Kumar A., Gao F., Montefiori D.C., Korber B. Genetic signatures in the envelope glycoproteins of HIV-1 that associate with broadly neutralizing antibodies. PLoS Comput. Biol. 2010, 6:e1000955. 10.1371/journal.pcbi.1000955.
25. Gómez-Román V.R., Florese R.H., Patterson L.J., Peng B., Venzon D., Aldrich K., Robert-Guroff M. A simplified method for the rapid fluorometric assessment of antibody-dependent cell-mediated cytotoxicity. J. Immunol. Methods 2006, 308:53-67. 10.1016/j.jim.2005.09.018.
26. Gorny M.K., Sampson J., Li H., Jiang X., Totrov M., Wang X.-H., Williams C., O'Neal T., Volsky B., Li L., Cardozo T., Nyambi P., Zolla-Pazner S., Kong X.-P. Human anti-V3 HIV-1 monoclonal antibodies encoded by the VH5-51/VL lambda genes define a conserved antigenic structure. PLoS One 2011, 6:e27780. 10.1371/journal.pone.0027780.
27. Gorny M.K., Wang X.-H., Williams C., Volsky B., Revesz K., Witover B., Burda S., Urbanski M., Nyambi P., Krachmarov C., Pinter A., Zolla-Pazner S., Nadas A. Preferential use of the VH5-51 gene segment by the human immune response to code for antibodies against the V3 domain of HIV-1. Mol. Immunol. 2009, 46:917-926. 10.1016/j.molimm.2008.09.005.
28. Graham F.L., Smiley J., Russell W.C., Nairn R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol. 1977, 36:59-74.
29. Gray E.S., Madiga M.C., Hermanus T., Moore P.L., Wibmer C.K., Tumba N.L., Werner L., Mlisana K., Sibeko S., Williamson C., Abdool Karim S.S., Morris L., Team the C.S The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection. J. Virol 2011, 85:4828-4840. 10.1128/JVI.00198-11.
30. Han Y., Wang X., Dang Y., Zheng Y.-H. Demonstration of a novel HIV-1 restriction phenotype from a human T cell line. PLoS One 2008, 3:e2796.
31. Haynes B.F., Gilbert P.B., McElrath M.J., Zolla-Pazner S., Tomaras G.D., Alam S.M., Evans D.T., Montefiori D.C., Karnasuta C., Sutthent R., Liao H.-X.X., DeVico A.L., Lewis G.K., Williams C., Pinter A., Fong Y., Janes H., DeCamp A., Huang Y., Rao M., Billings E., Karasavvas N., Robb M.L., Ngauy V., de Souza M.S., Paris R., Ferrari G., Bailer R.T., Soderberg K.A., Andrews C., Berman P.W., Frahm N., De Rosa S.C., Alpert M.D., Yates N.L., Shen X., Koup R.A., Pitisuttithum P., Kaewkungwal J., Nitayaphan S., Rerks-Ngarm S., Michael N.L., Kim J.H. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N. Engl. J. Med. 2012, 366:1275-1286. 10.1056/NEJMoa1113425.
32. Haynes B.F., Kelsoe G., Harrison S.C., Kepler T.B. B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study. Nat. Biotechnol. 2012, 30:423-433. 10.1038/nbt.2197.
33. Hessell A.J., Hangartner L., Hunter M., Havenith C.E.G., Beurskens F.J., Bakker J.M., Lanigan C.M.S., Landucci G., Forthal D.N., Parren P.W.H.I., Marx P.A., Burton D.R. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 2007, 449:101-104. 10.1038/nature06106.
34. Hessell A.J., Poignard P., Hunter M., Hangartner L., Tehrani D.M., Bleeker W.K., Parren P.W.H.I., Marx P.A., Burton D.R. Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat. Med. 2009, 15:951-954. 10.1038/nm.1974.
35. Hessell A.J., Rakasz E.G., Poignard P., Hangartner L., Landucci G., Forthal D.N., Koff W.C., Watkins D.I., Burton D.R. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog. 2009, 5:e1000433. 10.1371/journal.ppat.1000433.
36. Hessell A.J., Rakasz E.G., Tehrani D.M., Huber M., Weisgrau K.L., Landucci G., Forthal D.N., Koff W.C., Poignard P., Watkins D.I., Burton D.R. Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L. J. Virol. 2010, 84:1302-1313. 10.1128/JVI.01272-09.
37. Howell D., Andreotti J., Cresswell P. Natural killing target antigens as inducers of interferon; studies with an immunoselected, natural-killing-resistant human T-lymphoblastoid cell line. J. Immunol. 1985, 134:971-976.
38. Huang C., Tang M., Zhang M.-Y., Majeed S., Montabana E., Stanfield R.L., Dimitrov D.S., Korber B., Sodroski J., Wilson I.A., Wyatt R., Kwong P.D. Structure of a V3-containing HIV-1 gp120 core. Science 2005, 310:1025-1028. 10.1126/science.1118398.
39. Huang C., Venturi M., Majeed S., Moore M.J., Phogat S., Zhang M.-Y., Dimitrov D.S., Hendrickson W.A., Robinson J., Sodroski J., Wyatt R., Choe H., Farzan M., Kwong P.D. Structural basis of tyrosine sulfation and VH-gene usage in antibodies that recognize the HIV type 1 coreceptor-binding site on gp120. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:2706-2711. 10.1073/pnas.0308527100.
40. Huber M., Le K.M., Doores K.J., Fulton Z., Stanfield R.L., Wilson I.a., Burton D.R. Very few substitutions in a germ line antibody are required to initiate significant domain exchange. J. Virol. 2010, 84:10700-10707. 10.1128/JVI.01111-10.
41. Javaherian K., Langlois A.J., McDanal C., Ross K.L., Eckler L.I., Jellis C.L., Profy A.T., Rusche J.R., Bolognesi D.P., Putney S.D. Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein. Proc. Natl. Acad. Sci. U.S.A 1989, 86:6768-6772.
42. Jiang X., Burke V., Totrov M., Williams C., Cardozo T., Gorny M.K., Zolla-Pazner S., Kong X.-P. Conserved structural elements in the V3 crown of HIV-1 gp120. Nat. Struct. Mol. Biol. 2010, 17:955-961. 10.1038/nsmb.1861.
43. Keele B.F., Giorgi E.E., Salazar-Gonzalez J.F., Decker J.M., Pham K.T., Salazar M.G., Sun C., Grayson T., Wang S., Li H., Wei X., Jiang C., Kirchherr J.L., Gao F., Anderson J.A., Ping L.-H., Swanstrom R., Tomaras G.D., Blattner W.A., Goepfert P.a., Kilby J.M., Saag M.S., Delwart E.L., Busch M.P., Cohen M.S., Montefiori D.C., Haynes B.F., Gaschen B., Athreya G.S., Lee H.Y., Wood N., Seoighe C., Perelson A.S., Bhattacharya T., Korber B.T., Hahn B.H., Shaw G.M. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc. Natl. Acad. Sci. U.S.A 2008, 105:7552-7557. 10.1073/pnas.0802203105.
44. Klein F., Diskin R., Scheid J.F., Gaebler C., Mouquet H., Georgiev I.S., Pancera M., Zhou T., Incesu R.-B., Fu B.Z., Gnanapragasam P.N.P., Oliveira T.Y., Seaman M.S., Kwong P.D., Bjorkman P.J., Nussenzweig M.C. Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization. Cell 2013, 153:126-138. 10.1016/j.cell.2013.03.018.
45. Klein F., Halper-Stromberg A., Horwitz J.A., Gruell H., Scheid J.F., Bournazos S., Mouquet H., Spatz L.A., Diskin R., Abadir A., Zang T., Dorner M., Billerbeck E., Labitt R.N., Gaebler C., Marcovecchio P.M., Incesu R.-B., Eisenreich T.R., Bieniasz P.D., Seaman M.S., Bjorkman P.J., Ravetch J.V., Ploss A., Nussenzweig M.C. HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature 2012, 492:118-122. 10.1038/nature11604.
46. Kuwata T., Katsumata Y., Takaki K., Miura T., Igarashi T. Isolation of potent neutralizing monoclonal antibodies from an SIV-infected rhesus macaque by phage display. AIDS Res. Hum. Retroviruses 2011, 27:487-500. 10.1089/aid.2010.0191.
47. Kwong P.D., Doyle M.L., Casper D.J., Cicala C., Leavitt S.A., Majeed S., Steenbeke T.D., Venturi M., Chaiken I., Fung M., Katinger H., Parren P.W.I.H., Robinson J., Ryk D., Van, Wang L., Burton D.R., Freire E., Wyatt R., Sodroski J., Hendrickson W.A., Arthos J. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 2002, 420:678-682. 10.1038/nature01272.Published.
48. Kwong P.D., Wyatt R., Robinson J., Sweet R.W., Sodroski J., Hendrickson W.A. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998, 393:648-659. 10.1038/31405.
49. Lambotte O., Ferrari G., Moog C., Yates N.L., Liao H.-X., Parks R.J., Hicks C.B., Owzar K., Tomaras G.D., Montefiori D.C., Haynes B.F., Delfraissy J.-F. Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers. AIDS 2009, 23:897-906. 10.1097/QAD.0b013e328329f97d.
50. Lee H.Y., Giorgi E.E., Keele B.F., Gaschen B., Athreya G.S., Salazar-Gonzalez J.F., Pham K.T., Goepfert P.A., Kilby J.M., Saag M.S., Delwart E.L., Busch M.P., Hahn B.H., Shaw G.M., Korber B.T., Bhattacharya T., Perelson A.S. Modeling sequence evolution in acute HIV-1 infection. J. Theor. Biol. 2009, 261:341-360. 10.1016/j.jtbi.2009.07.038.
51. Lewis G.K., Fouts T.R., Ibrahim S., Taylor B.M., Salkar R., Guan Y., Kamin-Lewis R., Robinson J.E., Devico A.L. Identification and characterization of an immunogenic hybrid epitope formed by both HIV gp120 and human CD4 proteins. J. Virol. 2011, 85:13097-13104. 10.1128/JVI.05072-11.
52. Li M., Gao F., Mascola J.R., Stamatatos L., Polonis V.R., Koutsoukos M., Voss G., Goepfert P., Gilbert P., Greene K.M., Bilska M., Kothe D.L., Salazar-gonzalez J.F., Wei X., Decker J.M., Hahn B.H., Montefiori D.C. Human immunodeficiency virus type 1 Env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J. Virol. 2005, 79:10108-10125. 10.1128/JVI.79.16.10108.
53. Li M., Salazar-Gonzalez J.F., Derdeyn C.A., Morris L., Williamson C., Robinson J.E., Decker J.M., Li Y., Salazar M.G., Polonis V.R., Mlisana K., Karim S.A., Hong K., Greene K.M., Bilska M., Zhou J., Allen S., Chomba E., Mulenga J., Vwalika C., Gao F., Zhang M., Korber B.T.M., Hunter E., Hahn B.H., Montefiori D.C. Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa. J. Virol. 2006, 80:11776-11790. 10.1128/JVI.01730-06.
54. Liao H., Guo J., Lange M.D., Fan R., Zemlin M., Su K., Guan Y., Zhang Z. Contribution of VH replacement products to the generation of anti-HIV antibodies. Clin. Immunol. 2013, 146:46-55. 10.1016/j.clim.2012.11.003.
55. Liu J., Bartesaghi A., Borgnia M.J., Sapiro G., Subramaniam S. Molecular architecture of native HIV-1 gp120 trimers. Nature 2008, 455:109-113. 10.1038/nature07159.
56. Lusso P., Earl P.L., Sironi F., Santoro F., Ripamonti C., Scarlatti G., Longhi R., Berger E.A., Burastero S.E. Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains. J. Virol. 2005, 79:6957-6968. 10.1128/JVI.79.11.6957-6968.2005.
57. Lyerly H., Reed D., Matthews T., Langlois A., Ahearne P., Petteway S., Weinhold K. Anti-gp120 antibodies from HIV seropositive individuals mediate broadly reactive anti-HIV ADCC. AIDS Res. Hum. Retroviruses 1987, 3:409-422.
58. Madhavi V., Wren L.H., Gonelli C., Winnall W.R., Parsons M.S., Kramski M., Kent S.J., Stratov I. Breadth of HIV-1 Env-specific antibody-dependent cellular cytotoxicity[U+202F]: relevance to global HIV vaccine design. AIDS 2014, 28:1859-1870. 10.1097/QAD.0000000000000310.
59. Maeda K., Yoshimura K., Shibayama S., Habashita H., Tada H., Sagawa K., Miyakawa T., Aoki M., Fukushima D., Mitsuya H. Novel low molecular weight spirodiketopiperazine derivatives potently inhibit R5 HIV-1 infection through their antagonistic effects on CCR5. J. Biol. Chem. 2001, 276:35194-35200. 10.1074/jbc.M105670200.
60. Marasco W.A., Sui J. The growth and potential of human antiviral monoclonal antibody therapeutics. Nat. Biotechnol. 2007, 25:1421-1434. 10.1038/nbt1363.
61. Mascola J.R., Lewis M.G., Stiegler G., Vancott T.C., Hayes D., Louder M.K., Brown C.R., Sapan C.V., Frankel S.S., Lu Y., Robb M.L., Katinger H., Birx L., Harris D., Cott T.C.V.A.N., Birx D.L. Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J. Virol. 1999, 73:4009-4018.
62. Mascola J.R., Stiegler G., VanCott T.C., Katinger H., Carpenter C.B., Hanson C.E., Beary H., Hayes D., Frankel S.S., Birx D.L., Lewis M.G. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat. Med 2000, 6:207-210. 10.1038/72318.
63. Matsushita S., Robert-Guroff M., Trepel J., Cossman J., Mitsuya H., Broder S. Human monoclonal antibody directed against an envelope glycoprotein of human T-cell leukemia virus type I. Proc. Natl. Acad. Sci. 1986, 83:2672-2676.
64. Mbah H.A., Burda S., Gorny M.K., Williams C., Revesz K., Zolla-Pazner S., Nyambi P.N. Effect of soluble CD4 on exposure of epitopes on primary, intact, native human immunodeficiency virus type 1 virions of different genetic clades. J. Virol. 2001, 75:7785-7788. 10.1128/JVI.75.16.7785-7788.2001.
65. McGuire A.T., Glenn J.A., Lippy A., Stamatatos L. Diverse recombinant HIV-1 Envs fail to activate B cells expressing the germline B cell receptors of the broadly neutralizing anti-HIV-1 antibodies PG9 and 447-52D. J. Virol. 2014, 88:2645-2657. 10.1128/JVI.03228-13.
66. Moldt B., Rakasz E.G., Schultz N., Chan-Hui P.-Y., Swiderek K., Weisgrau K.L., Piaskowski S.M., Bergman Z., Watkins D.I., Poignard P., Burton D.R. Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo. Proc. Natl. Acad. Sci. U.S.A 2012, 109:18921-18925. 10.1073/pnas.1214785109.
67. Monde K., Maeda Y., Tanaka Y., Harada S., Yusa K. Gp120 V3-dependent impairment of R5 HIV-1 infectivity due to virion-incorporated CCR5. J. Biol. Chem. 2007, 282:36923-36932. 10.1074/jbc.M705298200.
68. TM 2009, 395-405. Humana Press. 10.1007/978-1-59745-170-3_26. V. Prasad, G. Kalpana (Eds.).
69. Montessori V., Press N., Harris M., Akagi L., Montaner J.S.G. Adverse effects of antiretroviral therapy for HIV infection. CMAJ 2004, 170:229-238.
70. Moore J.P., Cao Y., Ho D.D., Koup R.A. Development of the anti-gp120 antibody response during seroconversion to human immunodeficiency virus type 1. J. Virol. 1994, 68:5142-5155.
71. Moulard M., Phogat S.K., Shu Y., Labrijn A.F., Xiao X., Binley J.M., Zhang M.-Y., Sidorov I.A., Broder C.C., Robinson J., Parren P.W.H.I., Burton D.R., Dimitrov D.S. Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes. Proc. Natl. Acad. Sci. U.S.A 2002, 99:6913-6918. 10.1073/pnas.102562599.
72. Nag P., Kim J., Sapiega V., Landay A.L., Bremer J.W., Mestecky J., Reichelderfer P., Kovacs A., Cohn J., Weiser B., Baum L.L. Women with cervicovaginal antibody-dependent cell-mediated cytotoxicity have lower genital HIV-1 RNA loads. J. Infect. Dis. 2004, 190:1970-1978. 10.1086/425582.
73. Naik E., Casanas B., Pazare A., Wabale G., Sinnott J., Salihu H. Cost of treatment: the single biggest obstacle to HIV/AIDS treatment adherence in lower-middle class patients in Mumbai. India. Indian J. Sex. Transm. Dis. AIDS 2009, 30:23-27. 10.4103/0253-7184.55476.
74. Ng C.T., Jaworski J.P., Jayaraman P., Sutton W.F., Delio P., Kuller L., Anderson D., Landucci G., Richardson B.a., Burton D.R., Forthal D.N., Haigwood N.L. Passive neutralizing antibody controls SHIV viremia and enhances B cell responses in infant macaques. Nat. Med. 2010, 16:1117-1119. 10.1038/nm.2233.
75. Nkolola J.P., Bricault C.a., Cheung A., Shields J., Perry J., Kovacs J.M., Giorgi E., van Winsen M., Apetri A., Brinkman-van der Linden E.C.M., Chen B., Korber B., Seaman M.S., Barouch D.H. Characterization and immunogenicity of a novel mosaic M HIV-1 gp140 trimer. J. Virol. 2014, 88:9538-9552. 10.1128/JVI.01739-14.
76. O'Doherty U., Swiggard W.J., Malim M.H. Human immunodeficiency virus type 1 spinoculation enhances infection through virus binding. J. Virol. 2000, 74:10074-10080. 10.1128/JVI.74.21.10074-10080.2000.
77. Ochsenbauer C., Edmonds T.G., Ding H., Keele B.F., Decker J., Salazar M.G., Salazar-Gonzalez J.F., Shattock R., Haynes B.F., Shaw G.M., Hahn B.H., Kappes J.C. Generation of transmitted/founder HIV-1 infectious molecular clones and characterization of their replication capacity in CD4 T lymphocytes and monocyte-derived macrophages. J. Virol. 2012, 86:2715-2728. 10.1128/JVI.06157-11.
78. Overbaugh J., Morris L. The antibody response against HIV-1. Cold Spring Harb. Perspect. Med 2012, 2:a007039. 10.1101/cshperspect.a007039.
79. Palmer S., Maldarelli F., Wiegand A., Bernstein B., Hanna G.J., Brun S.C., Kempf D.J., Mellors J.W., Coffin J.M., King M.S. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc. Natl. Acad. Sci. U.S.A 2008, 105:3879-3884. 10.1073/pnas.0800050105.
80. Parren P.W.H.I., Marx P.A., Hessell A.N.N.J., Harouse J., Cheng-mayer C., John P., Burton D.R., Luckay A., Moore J.P. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J. Virol. 2001, 75:8340-8347. 10.1128/JVI.75.17.8340-8347.2001.
81. Platt E.J., Wehrly K., Kuhmann S.E., Chesebro B., Kabat D. Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J. Virol. 1998, 72:2855-2864.
82. Pollara J., Bonsignori M., Moody M.A., Liu P., Alam S.M., Hwang K.-K., Gurley T.C., Kozink D.M., Armand L.C., Marshall D.J., Whitesides J.F., Kaewkungwal J., Nitayaphan S., Pitisuttithum P., Rerks-Ngarm S., Robb M.L., O'Connell R.J., Kim J.H., Michael N.L., Montefiori D.C., Tomaras G.D., Liao H.-X., Haynes B.F., Ferrari G. HIV-1 vaccine-induced C1 and V2 Env-specific antibodies synergize for increased antiviral activities. J. Virol. 2014, 88:7715-7726. 10.1128/JVI.00156-14.
83. Rader, C., Popkov, M., Neves, J.A., Barbas III, C.F., 2002. Integrin avb3-targeted therapy for Kaposi's sarcoma with an in vitro-evolved antibody. FASEB J. 10.1096/fj.02-0281fje.
84. Rerks-Ngarm S., Pitisuttithum P., Nitayaphan S., Kaewkungwal J., Chiu J., Paris R., Premsri N., Namwat C., de Souza M., Adams E., Benenson M., Gurunathan S., Tartaglia J., McNeil J.G., Francis D.P., Stablein D., Birx D.L., Chunsuttiwat S., Khamboonruang C., Thongcharoen P., Robb M.L., Michael N.L., Kunasol P., Kim J.H. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 2009, 361:2209-2220. 10.1056/NEJMoa0908492.
85. Reust C.E. Common adverse effects of antiretroviral therapy for HIV disease. Am. Fam. Phys. 2011, 83:1443-1451.
86. Richman D.D., Margolis D.M., Delaney M., Greene W.C., Hazuda D., Pomerantz R.J. The challenge of finding a cure for HIV infection. Science. 323 2009, 80:1304-1307.
87. Roederer M., Keele B.F., Schmidt S.D., Mason R.D., Welles H.C., Fischer W., Labranche C., Foulds K.E., Louder M.K., Yang Z.-Y., Todd J.-P.M., Buzby A.P., Mach L.V., Shen L., Seaton K.E., Ward B.M., Bailer R.T., Gottardo R., Gu W., Ferrari G., Alam S.M., Denny T.N., Montefiori D.C., Tomaras G.D., Korber B.T., Nason M.C., Seder R.A., Koup R.A., Letvin N.L., Rao S.S., Nabel G.J., Mascola J.R. Immunological and virological mechanisms of vaccine-mediated protection against SIV and HIV. Nature 2014, 505:502-508. 10.1038/nature12893.
88. Salazar-Gonzalez J.F., Bailes E., Pham K.T., Salazar M.G., Guffey M.B., Keele B.F., Derdeyn C.a., Farmer P., Hunter E., Allen S., Manigart O., Mulenga J., Anderson J.A., Swanstrom R., Haynes B.F., Athreya G.S., Korber B.T.M., Sharp P.M., Shaw G.M., Hahn B.H. Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing. J. Virol. 2008, 82:3952-3970. 10.1128/JVI.02660-07.
89. Salazar-Gonzalez J.F., Salazar M.G., Keele B.F., Learn G.H., Giorgi E.E., Li H., Decker J.M., Wang S., Baalwa J., Kraus M.H., Parrish N.F., Shaw K.S., Guffey M.B., Bar K.J., Davis K.L., Ochsenbauer-Jambor C., Kappes J.C., Saag M.S., Cohen M.S., Mulenga J., Derdeyn C.A., Allen S., Hunter E., Markowitz M., Hraber P., Perelson A.S., Bhattacharya T., Haynes B.F., Korber B.T., Hahn B.H., Shaw G.M. Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J. Exp. Med. 2009, 206:1273-1289. 10.1084/jem.20090378.
90. Sather D.N., Armann J., Ching L.K., Mavrantoni A., Sellhorn G., Caldwell Z., Yu X., Wood B., Self S., Kalams S., Stamatatos L. Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J. Virol. 2009, 83:757-769. 10.1128/JVI.02036-08.
91. Scheid J.F., Mouquet H., Ueberheide B., Diskin R., Klein F., Oliveira T.Y.K., Pietzsch J., Fenyo D., Abadir A., Velinzon K., Hurley A., Myung S., Boulad F., Poignard P., Burton D.R., Pereyra F., Ho D.D., Walker B.D., Seaman M.S., Bjorkman P.J., Chait B.T., Nussenzweig M.C. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science. 333 2011, 80:1633-1637. 10.1126/science.1207227, 10.1126/science.1207227.
92. Seaman M.S., LeBlanc D.F., Grandpre L.E., Bartman M.T., Montefiori D.C., Letvin N.L., Mascola J.R. Standardized assesment of NAb responses elicited in rhesus monkeys immunized with single- or multi-clade HIV-1 envelope immunogens. Virology 2007, 367:175-186.
93. Seaman M.S., Xu L., Beaudry K., Kristi L., Beddall M.H., Miura A., Sambor A., Chakrabarti B.K., Huang Y., Bailer R., Richard A., Mascola J.R., Nabel G.J., Letvin N.L. Multiclade human immunodeficiency virus type 1 envelope immunogens elicit broad cellular and humoral immunity in rhesus monkeys. J. Virol. 2005, 79:2956-2963. 10.1128/JVI.79.5.2956.
94. Shibata R., Igarashi T., Haigwood N., Buckler-White A., Ogert R., Ross W., Willey R., Cho M.W., Martin M.A. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat. Med 1999, 5:204-210. 10.1038/5568.
95. Simek M.D., Rida W., Priddy F.H., Pung P., Carrow E., Laufer D.S., Lehrman J.K., Boaz M., Tarragona-Fiol T., Miiro G., Birungi J., Pozniak A., McPhee D.A., Manigart O., Karita E., Inwoley A., Jaoko W., DeHovitz J., Bekker L.-G., Pitisuttithum P., Paris R., Walker L.M., Poignard P., Wrin T., Fast P.E., Burton D.R., Koff W.C. Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm. J. Virol. 2009, 83(7337-7348). 10.1128/JVI.00110-09.
96. Smalls-Mantey A., Doria-Rose N., Klein R., Patamawenu A., Migueles S.A., Ko S.-Y., Hallahan C.W., Wong H., Liu B., You L., Scheid J., Kappes J.C., Ochsenbauer C., Nabel G.J., Mascola J.R., Connors M. Antibody-dependent cellular cytotoxicity against primary HIV-infected CD4+ T cells is directly associated with the magnitude of surface IgG binding. J. Virol. 2012, 86:8672-8680. 10.1128/JVI.00287-12.
97. Sok D., Laserson U., Laserson J., Liu Y., Vigneault F., Julien J.-P., Briney B., Ramos A., Saye K.F., Le K., Mahan A., Wang S., Kardar M., Yaari G., Walker L.M., Simen B.B., St.John E.P., Chan-Hui P.-Y., Swiderek K., Kleinstein S.H., Alter G., Seaman M.S., Chakraborty A.K., Koller D., Wilson I.A., Church G.M., Burton D.R., Poignard P. The effects of somatic hypermutation on neutralization and binding in the PGT121 family of broadly neutralizing HIV antibodies. PLoS Pathog 2013, 9:e1003754.
98. Stamatatos L., Morris L., Burton D.R., Mascola J.R. Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine. Nat. Med. 2009, 15:866-870. 10.1038/nm.1949.
99. Takeuchi Y., McClure M.O., Pizzato M. Identification of gammaretroviruses constitutively released from cell lines used for human immunodeficiency virus research. J. Virol. 2008, 82:12585-12588. 10.1128/JVI.01726-08.
100. Tamura K., Peterson D., Peterson N., Stecher G., Nei M., Kumar S. MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol. Biol. Evol. 2011, 28:2731-2739. 10.1093/molbev/msr121.
101. Thali M., Moore J.P., Furman C., Charles M., Ho D.D., Robinson J., Sodroski J. Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding. J. Virol. 1993, 67:3978-3988.
102. Trkola A., Matthews J., Gordon C., Ketas T., Moore J.P. A cell line-based neutralization assay for primary human immunodeficiency virus type 1 isolates that use either the CCR5 or the CXCR4 coreceptor. J. Virol. 1999, 73:8966-8974.
103. Veazey R., Shattock R.J., Pope M., Kirijan J.C., Jones J., Qinxue H., Ketas T., Preston M., Klasse P.J., Burton D.R., Moore J.P. Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat. Med. 2003, 9:343-346. 10.1038/nm.
104. Veillette M., Désormeaux A., Medjahed H., Gharsallah N.-E., Coutu M., Baalwa J., Guan Y., Lewis G., Ferrari G., Hahn B.H., Haynes B.F., Robinson J.E., Kaufmann D.E., Bonsignori M., Sodroski J., Finzi A. Interaction with cellular CD4 exposes HIV-1 envelope epitopes targeted by antibody-dependent cell-mediated cytotoxicity. J. Virol. 2014, 88:2633-2644. 10.1128/JVI.03230-13.
105. Walker L.M., Huber M., Doores K.J., Falkowska E., Pejchal R., Julien J.-P., Wang S.-K., Ramos A., Chan-Hui P.-Y., Moyle M., Mitcham J.L., Hammond P.W., Olsen O.A., Phung P., Fling S., Wong C.-H., Phogat S., Wrin T., Simek M.D., Principal Investigators P.G., Koff W.C., Wilson I.A., Burton D.R., Poignard P. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 2011, 477:466-470.
106. Walker L.M., Phogat S.K., Chan-Hui P.-Y., Wagner D., Phung P., Goss J.L., Wrin T., Simek M.D., Fling S., Mitcham J.L., Lehrman J.K., Priddy F.H., Olsen O.a., Frey S.M., Hammond P.W., Kaminsky S., Zamb T., Moyle M., Koff W.C., Poignard P., Burton D.R. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science. 326 2009, 80:285-289. 10.1126/science.1178746, 10.1126/science.1178746.
107. Wei X., Decker J.M., Liu H., Zhang Z., Arani R.B., Kilby J.M., Saag M.S., Wu X., Shaw G.M., Kappes J.C. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. 2002, 46:1896-1905. 10.1128/AAC.46.6.1896.
108. Wren L., Parsons M.S., Isitman G., Center R.J., Kelleher A.D., Stratov I., Bernard N.F., Kent S.J. Influence of cytokines on HIV-specific antibody-dependent cellular cytotoxicity activation profile of natural killer cells. PLoS One 2012, 7:e38580.
109. Wren L.H., Chung A.W., Isitman G., Kelleher A.D., Parsons M.S., Amin J., Cooper D.A., Stratov I., Navis M., Kent S.J. Specific antibody-dependent cellular cytotoxicity responses associated with slow progression of HIV infection. Immunology 2013, 138:116-123. 10.1111/imm.12016.
110. Wu X., Sambor A., Nason M.C., Yang Z.-Y., Wu L., Zolla-Pazner S., Nabel G.J., Mascola J.R. Soluble CD4 broadens neutralization of V3-directed monoclonal antibodies and guinea pig vaccine sera against HIV-1 subtype B and C reference viruses. Virology 2008, 380:285-295. 10.1016/j.virol.2008.07.007.
111. Wu X., Zhou T., Zhu J., Zhang B., Georgiev I., Wang C., Chen X., Longo N.S., Louder M., McKee K., O'Dell S., Perfetto S., Schmidt S.D., Shi W., Wu L., Yang Y., Yang Z.-Y.Z., Zhang Z., Bonsignori M., Crump J.A., Kapiga S.H., Sam N.E., Haynes B.F., Simek M., Burton D.R., Koff W.C., Doria-Rose N.A., Connors M., Program N.C.S., Mullikin J.C., Nabel G.J., Roederer M., Shapiro L., Kwong P.D., Mascola J.R., O'Dell S. Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science 2011, 333:1593-1602. 10.1126/science.1207532.
112. Xiang S., Doka N., Choudhary R.K., Sodroski J., Robinson J.E. Characterization of CD4-induced epitopes on the HIV type 1 gp120 envelope glycoprotein recognized by neutralizing human monoclonal antibodies. AIDS Res. Hum. Retroviruses 2002, 18:1207-1217.
113. Xiao P., Zhao J., Patterson L.J., Brocca-Cofano E., Venzon D., Kozlowski P.A., Hidajat R., Demberg T., Robert-Guroff M. Multiple vaccine-elicited nonneutralizing antienvelope antibody activities contribute to protective efficacy by reducing both acute and chronic viremia following simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques. J. Virol. 2010, 84:7161-7173. 10.1128/JVI.00410-10.
114. Xiao X., Chen W., Feng Y., Zhu Z., Prabakaran P., Wang Y., Zhang M.-Y., Longo N.S., Dimitrov D.S. Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: implications for evasion of immune responses and design of vaccine immunogens. Biochem. Biophys. Res. Commun. 2009, 390:404-409. 10.1016/j.bbrc.2009.09.029.
115. Yoshimura K., Shibata J., Kimura T., Honda A., Maeda Y., Koito A., Murakami T., Mitsuya H., Matsushita S. Resistance profile of a neutralizing anti-HIV monoclonal antibody, KD-247, that shows favourable synergism with anti-CCR5 inhibitors. AIDS 2006, 20:2065-2073. 10.1097/01.aids.0000247587.31320.fe.
116. Zhou T., Georgiev I., Wu X., Yang Z.-Y., Dai K., Finzi A., Do Kwon Y., Scheid J.F., Shi W., Xu L., Yang Y., Zhu J., Nussenzweig M.C., Sodroski J., Shapiro L., Nabel G.J., Mascola J.R., Kwong P.D. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 2010, 329:811-817. 10.1126/science.1192819.
117. Zhu J., Wu X., Zhang B., McKee K., O'Dell S., Soto C., Zhou T., Casazza J.P., Program N.C.S., Mullikin J.C., Kwong P.D., Mascola J.R., Shapiro L. De novo identification of VRC01 class HIV-1-neutralizing antibodies by next-generation sequencing of B-cell transcripts. Proc. Natl. Acad. Sci. 2013, 110:E4088-E4097. 10.1073/pnas.1306262110.
118. Zolla-Pazner S. Identifying epitopes of HIV-1 that induce protective antibodies. Nat. Rev. Immunol. 2004, 4:199-210. 10.1038/nri1307.
119. Zolla-Pazner S. A critical question for HIV vaccine development: which antibodies to induce. Science. 345 2014, 80:167-168. 10.1126/science.1256526, 10.1126/science.1256526.
120. Zolla-Pazner S., Kong X.-P., Jiang X., Cardozo T., Nádas A., Cohen S., Totrov M., Seaman M.S., Wang S., Lu S. Cross-clade HIV-1 neutralizing antibodies induced with V3-scaffold protein immunogens following priming with gp120 DNA. J. Virol. 2011, 85:9887-9898. 10.1128/JVI.05086-11.
121. Zuo T., Shi X., Liu Z., Guo L., Zhao Q., Guan T., Pan X., Jia N., Cao W., Zhou B., Goldin M., Zhang L. Comprehensive analysis of pathogen-specific antibody response in vivo based on an antigen library displayed on surface of yeast. J. Biol. Chem. 2011, 286:33511-33519. 10.1074/jbc.M111.270553.